1 Result(s)

Article

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

Preclinical and clinical data suggest that fibroblast growth factor 21 (FGF21) is anti-fibrotic, improves metabolic status and has potential to treat non-alcoholic steatohepatitis (NASH). We assessed the safet...

Stephen A. Harrison, Peter J. Ruane, Bradley L. Freilich, Guy Neff… in Nature Medicine (2021)